pharma · Paroxysmal Nocturnal Hemoglobinuria (PNH) · Paroxysmal Nocturnal Haemoglobinuria (PNH) · AKTX
Akari Therapeutics
Akari Therapeutics Plc
Akari Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- London, GB
- Employees
- 16
- Programs
- 9
- Drugs
- 0
- Patents
- 0
Akari Therapeutics projects
4 ClinicalTrials.gov programs sponsored by Akari Therapeutics.
Akari Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
nomacopan (rVA576)
Akari Therapeutics Plc
Bullous Pemphigoid
1 trial -
nomacopan (rVA576)
Akari Therapeutics Plc
Thrombotic Microangiopathies
1 trial -
rVA576
Akari Therapeutics Plc
Paroxysmal Nocturnal Hemoglobinuria
1 trial -
rVA576
Akari Therapeutics Plc
Paroxysmal Nocturnal Hemoglobinuria (PNH)
1 trial
Frequently asked questions
How many clinical projects does Akari Therapeutics have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.